John Tattory - Windtree Therapeutics CFO, Senior Vice President
| WINT Stock | USD 0.13 0.00 0.00% |
President
Mr. John A. Tattory is Chief Financial Officer and Senior Vice President of Discovery Laboratories Inc., effective March 2014. He previously served as our Vice President, Finance and Chief Accounting Officer, and our Vice President, Finance, and Controller and the designated principal accounting officer, and Vice President, Finance . He brings more than 20 years of finance and accounting experience, including at Tyco International, where he served as Director, Financial Planning Analysis for Tyco Flow Control, an operating unit that included the majority of business operations in international markets and eight years at BristolMyers Squibb, where he held financial roles of increasing responsibility, most recently as Finance Director, U.S. Primary Care, with responsibility for the financial matters of various BMS pharmaceutical businesses, including international operations. Mr. Tattory also spent eight years with Ernst Young LLP in the firms audit practice since 2014.
| Age | 58 |
| Tenure | 11 years |
| Professional Marks | CPA |
| Address | 2600 Kelly Road, Warrington, PA, United States, 18976-3622 |
| Phone | 215 488 9300 |
| Web | https://windtreetx.com |
John Tattory Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Tattory against Windtree Therapeutics stock is an integral part of due diligence when investing in Windtree Therapeutics. John Tattory insider activity provides valuable insight into whether Windtree Therapeutics is net buyers or sellers over its current business cycle. Note, Windtree Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Windtree Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Tattory over six months ago Payment of 8007 shares by John Tattory of Windtree Therapeutics subject to Rule 16b-3 |
Windtree Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4476) % which means that it has lost $0.4476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.508) %, meaning that it created substantial loss on money invested by shareholders. Windtree Therapeutics' management efficiency ratios could be used to measure how well Windtree Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.42 in 2025. Return On Capital Employed is likely to drop to -0.58 in 2025. At this time, Windtree Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 42.3 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 16.4 M in 2025.Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Srinivas Subramanian | Avenue Therapeutics | 53 | |
Management Performance
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.45 |
Windtree Therapeutics Leadership Team
Elected by the shareholders, the Windtree Therapeutics' board of directors comprises two types of representatives: Windtree Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Windtree. The board's role is to monitor Windtree Therapeutics' management team and ensure that shareholders' interests are well served. Windtree Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Windtree Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Cox, Vice Operations | ||
| Eric MBA, Senior COO | ||
| Jamie McAndrew, Controller, VP | ||
| John Tattory, CFO, Senior Vice President | ||
| Pratap Paruchuru, Executive Development | ||
| Craig Fraser, President CEO, Director | ||
| Steven Simonson, Senior Vice President and Chief Development Officer | ||
| Ronald Dundore, Ex Quality | ||
| MHS MD, Senior Officer | ||
| Tracy Rarick, Head Management | ||
| Diane Esq, Sr Counsel | ||
| John CPA, CFO, VP |
Windtree Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Windtree Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 917.64 K | ||||
| Shares Outstanding | 8.75 M | ||||
| Shares Owned By Insiders | 0.27 % | ||||
| Shares Owned By Institutions | 0.59 % | ||||
| Number Of Shares Shorted | 909.04 K | ||||
| Price To Earning | (0.05) X | ||||
| Price To Book | 0.27 X | ||||
| Price To Sales | 660.53 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.